AdAlta CEO on shark antibody technology

December 16, 2016 Christoph Graener

AdAlta is developing a novel technology platform that engineers the key stability features of the antigen binding domain of shark antibodies into human proteins to create unique compounds, known as i-bodies, for therapeutic intervention in disease.
Sam Cobb, managing director and CEO of the Australian biotech, talks to Scrip senior writer Lucie Ellis about the company’s recent public listing and clinical development plans for lead product, AD-114, in idiopathic pulmonary fibrosis.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Sam Cobb – Managing Director and CEO, AdAlta

Previous Article
Opportunities For unpartnered assets

Steven Muntner, VP of deals at Informa Pharma Intelligence, discusses key takeaways from a recent report lo...

Next Article
Promethera extends series C on interest from Asian investors

Dr. John Tchelingerian, CEO of Promethera Biosciences, talks about developing innovative therapies for the ...